Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

An open‐label, parallel‐group, single‐dose study was conducted to assess the pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end‐stage renal disease (ESRD) on hemodialysis compared with 8 subjects with normal renal function. A single oral 5‐mg dose of apixaban was admin...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical pharmacology Vol. 56; no. 5; pp. 628 - 636
Main Authors:	Wang, Xiaoli, Tirucherai, Giridhar, Marbury, Thomas C., Wang, Jessie, Chang, Ming, Zhang, Donglu, Song, Yan, Pursley, Janice, Boyd, Rebecca A., Frost, Charles
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.05.2016 American College of Clinical Pharmacology Wiley Subscription Services, Inc
Subjects:	Adult apixaban Area Under Curve end-stage renal disease Factor Xa - analysis Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - blood Factor Xa Inhibitors - pharmacokinetics Factor Xa Inhibitors - pharmacology Female Hemodialysis Humans International Normalized Ratio Kidney diseases Kidney Failure, Chronic - blood Kidney Failure, Chronic - metabolism Kidney Failure, Chronic - therapy Male Medicare Middle Aged Partial Thromboplastin Time pharmacodynamics pharmacokinetics Prothrombin Time Pyrazoles - adverse effects Pyrazoles - blood Pyrazoles - pharmacokinetics Pyrazoles - pharmacology Pyridones - adverse effects Pyridones - blood Pyridones - pharmacokinetics Pyridones - pharmacology Renal Dialysis hemodialysis pharmacokinetics end-stage renal disease apixaban pharmacodynamics
ISSN:	0091-2700, 1552-4604, 1552-4604
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!